October 12, 2016

Novocure Enrolls First Patient in Phase 3 Pivotal Brain Metastases Trial

METIS phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer ST. HELIER, N.J., Oct. 12, 2016 (GLOBE NEWSWIRE) — Novocure (NASDAQ:NVCR) announced today that the first patient has been enrolled in the METIS trial,… Read More
learn more